Abstract Patients with fever and granulocytopenia are at risk of developing severe infection. We performed a prospective, randomized trial to evaluate the efficacy of low-dose cefepime plus amikacin (C-A) compared to lowdose piperacillin/tazobactam plus amikacin (PT-A). Patients received cefepime (2 g/12 h) plus amikacin (15 mg/kg/day) or piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin. A total of 317 episodes of febrile granulocytopenia in 190 patients were studied (152 in the C-A group, 165 in the PT-A group). A microbiologically documented infection was present in 53 (35%) episodes in the C-A group and 41 (25%) episodes in the PT-A group (p=ns); a clinically documented infection was observed in 39 (26%) and 47 (28%) episodes, respectively. Toxicity was observed in 6 (4%) episodes in the C-A group and in 5 (3%) episodes in the PT-A group. The antibiotic success rate (no change or addition of antibiotics) was recorded in 89 (59%) and 105 (64%) cases, respectively (p=ns). Mortality related to infection was similar in each arm (3.9% vs. 3.6%). Combination therapy of low-dose β-lactam with an aminoglycoside achieves very good response rates and low rates of toxicity. It might be an attractive option in an environment of increasing resistance among gram-negative bacteria.
Introduction
Empirical antibiotic therapy with broad-spectrum agents is essential in the management of patients with chemotherapyinduced neutropenia and fever [1] . The choice of antibiotics should be based on local epidemiological data, including the resistance patterns of usual causative pathogens.
There are different accepted antibiotic regimens for the treatment of the febrile episodes in patients with granulocytopenia. The combination of a β-lactam with antipseudomonal activity (piperacillin, ticarcillin) plus an aminoglycoside has been used since the 1970s with good results [2] , and it has been the most commonly used empirical treatment for years. More recently, other combinations with third-and fourth-generation cephalosporins plus an aminoglycoside have been validated (ceftazidime plus amikacin, cefepime plus amikacin) [3, 4] . Finally, antibiotic therapy with a single agent with a broad spectrum of activity (carbapenems, ceftazidime, cefepime) has been widely used because of similar efficacy and less toxicity as compared to the classic combination therapy [5] [6] [7] [8] [9] , particularly in the mid1990s, when the prevalence of Pseudomonas aeruginosa infections decreased in parallel with a progressive predominance of gram-positive coccal infections.
The interest of using a combination of a β-lactam antibiotic plus an aminoglycoside has been recently fueled by the emergence of a number of resistance mechanisms that limit the use of some of the best drugs available; multidrug-resistant non-fermenters infections, extendedspectrum β-lactamase (ESBL)-producing organisms, particularly among Escherichia coli, Klebsiella spp., and, less commonly, other Enterobacteriaceae, are resistant to most β-lactams. Last but not least, carbapenem resistance among Enterobacteriaceae is emerging in some parts of the world [10, 11] . Several reports have documented the emergence of KPC enzymes in Salmonella enterica, K. oxytoca, Enterobacter sp., E. coli, and Citrobacter freundii [12] [13] [14] . A recent report from New York documents the spread of E. coli possessing the plasmid-borne carbapenemase KPC-2 [15] . Very few new drugs that are active against multidrugresistant nosocomial gram-negative organisms are expected to be available for 5-10 years. For all of these reasons, clinicians are starting to again consider the use of aminoglycoside antibiotics [16] . This strategy allows for continued empiric use of third-and fourth-generation cephalosporins, and preserves the use of carbapenems, in an increasing resistance environment.
One important question to be solved and that has attracted increasing attention is the proper dosage of the antimicrobials. Thus, in the case of piperacillin/tazobactam, 4 g/500 mg q/6 h is an approved dosing regimen for fever and granulocytopenia [5, 17, 18] , and in the case of cefepime, 2 g/8 h is the standard of care in this setting [6, [18] [19] [20] . However, lower doses of both antibiotics have been used in some studies [4, 9, 21, 22] . When a combination of agents is used, it is plausible that lower dosing can be administered [23] . In this scenario, the decreased dosage affords the same antibacterial activity and reduces toxicity and pharmacy costs.
The aim of our study was to compare the efficacy of a low dosage regimen of piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin (15 mg/kg/day) vs. low dosage of cefepime (2 g/12 h) plus amikacin (15 mg/kg/day) in the treatment of patients with fever and granulocytopenia, a regimen that has not been previously compared.
Methods
This was a prospective, randomized, open-label, phase IV clinical trial conducted in a single center. Our hospital is an acute care teaching referral institution in the province of Barcelona, Spain, which covers a health district of 320,000 inhabitants. It has 500 beds and approximately 26,000 patients are admitted to the hospital each year. It has a hemato-oncology unit with 22 inpatient rooms and an active autologous peripheral blood stem cell transplantation program. Patients aged >18 years with an episode of fever and granulocytopenia were eligible. Fever was defined as axillary T>37.8°C on two occasions separated by at least 4 h, and granulocytopenia was defined as an absolute neutrophil count <500 cells/mm 3 or <1,000 cells/mm 3 if a decline to <500 cells/mm 3 was expected in 24-48 h.
Patient eligibility
Patients were eligible if they had a creatinine <2 mg/dl, a life expectancy >3 months, a negative pregnancy test in the case of a potential child-bearing woman, and informed consent. Exclusion criteria were hypersensitivity to the study drugs, pregnant or lactating women, and parenteral antibiotic treatment within 72 h prior to study entry. The study was approved by the Ethics Committee of the hospital.
Randomization
The randomization list was performed with a random number generator computer program and the same patient could be included in different episodes of febrile granulocytopenia. [24] . Thus, treatment efficacy was considered when the resolution of signs and symptoms of infection plus the eradication of a pathogen, if it was initially present, was observed without any change or addition in the antibiotic course and it was maintained for at least 4 days after stopping treatment. Treatment failure occurred when there was persistence of fever (>37.8°C axillary) or other symptoms that led to a change/addition of antibiotic, when persistence of the pathogen >48 h (>24 h in the case of bacteremia) was observed, when in vitro resistance to the antibiotic was detected, or in case of breakthrough bacteremia, change or addition of the antibiotic, or death related to infection. Non-assessable episodes were considered when the primary infection was viral or fungal in origin, when a new febrile episode (after an initial response) led to a change in the antimicrobial treatment or the addition of antiviral/ antifungal agents, or when withdrawal from the study due to toxicity was required.
Final classification of the episode
The febrile episodes were classified as a microbiologically documented infection (MDI) with or without bacteremia, clinically documented infection (CDI), or fever of unknown origin (FUO), as previously defined [24] . Superinfection was defined as the presence of a new clinically or microbiologically documented infection that was not present at the beginning of the febrile episode.
Toxicity
All adverse events were classified following the World Health Organization criteria [25] . The degree of severity of the adverse event was defined as mild when the adverse event was resolved without stopping the drug, moderate when the adverse event required symptomatic treatment although the study drug could be continued, severe when the study drug had to be stopped, and lethal when the patient died due to the adverse event. Renal toxicity was defined by creatinine values two times higher than the initial values, if higher than 1.5 mg/dl.
The primary endpoint was the clinical efficacy of the two treatment arms at 4 days after the end of treatment. Secondary endpoints were microbiological eradication (microbiological response) and toxicity among the two groups of patients.
Withdrawal criteria
Withdrawal from the study was done when a severe adverse event occurred, the isolation of a resistant pathogen was found, or upon the request of the patient.
Statistical analysis
This was an equivalence trial, defined as an expected success in the treatment of 90% and a difference <10% between both arms. The sample size was calculated with a statistical power of 80% and an error of 0.05, and a 5% of patients lost to follow-up was estimated to occur. The number of episodes had to be 153 episodes for each arm. The evaluation of the efficacy was based in an intention-totreat analysis (all randomized patients who received at least one dose of the study drug were included in the analysis). Qualitative variables were compared with the use of the Chi 2 test or Fisher's exact test when needed, and quantitative variables were compared with the use of the MannWhitney test because the variables were not distributed normally. A p-value <0.05 was considered significant. The SPSS (version 12.0) software package was used to analyze the data.
Results
From March 1997 to November 2003, a total 317 episodes of febrile granulocytopenia in 190 adult patients were studied. Six febrile episodes did not meet all of the inclusion criteria and were excluded from the trial. The mean age of the sample was 60 years (range, 18-99), and there were 100 males and 90 females. Since patients could be randomized more than once to different treatment groups, the study was based on the evaluation of the 317 episodes; 131 patients were randomized only once, 30 patients were randomized twice, 11 patients were randomized on three occasions, 11 patients on four occasions, and eight patients on ≥5 occasions.
A total of 317 febrile episodes were studied (Table 1) : 152 episodes were randomized to the cefepime plus amikacin group (C-A) and 165 episodes to the piperacillin/ tazobactam plus amikacin group (PT-A). The presence of comorbidity was similar in the two groups. The main disease was acute leukemia/myelodysplastic syndrome in 83 (55%) and 84 (51%) of episodes in the C-A and PT-A group, respectively, lymphoma in 33 (22%) and 52 (31%), myeloma in 8 (5%) and 4 (2%) cases, and solid tumor in 19 episodes in both groups (12 and 11%, respectively) . No significant differences were found among groups.
General characteristics of the episodes (Table 1) : 126 (83%) and 134 (81%) of the cases in the C-A and PT-A APBSCT autologous peripheral blood stem cell transplantation;CVC central venous catheter;G-CSF granulocyte colony-stimulating growth factor groups had been exposed to prior chemotherapy, respectively; in 131 (86%) episodes in the C-A group and in 147 (89%) episodes in the PT-A group, the neoplasm was active. Previous steroid therapy (within 30 days) was recorded in 39 episodes (26%) in the C-A group and in 36 episodes (24%) in the PT-A group. Profound neutropenia (<100 cells/mm 3 ) was present in 63 episodes in each arm (41 and 38%, respectively, p=ns), and the median duration of neutropenia was 9 days in the C-A group compared to 7 days in the PT-A group (p=ns). Likewise, previous antibiotic treatment (within 30 days) and prophylaxis with trimethoprim/sulfamethoxazole did not differ between groups. No patient received prophylaxis with fluoroquinolones. The most common risk factor for infection was the presence of a central venous catheter (CVC) in 82 episodes (54%) and 83 episodes (50%) in the C-A and PT-A groups, respectively. Finally, no differences were observed between groups with respect to the median duration of the CVC line (14 and 13 days, respectively).
Description of febrile episodes ( Table 1 ): duration of fever was similar in both groups (median, 3 days), and there was a median of 1 day from the onset of neutropenia to the development of fever in both arms. In 70 (46%) episodes in the C-A group and in 69 (42%) episodes in the PT-A group, there were no clinical symptoms other than fever; gastrointestinal symptoms were observed in 37 (24%) and 46 (28%) of the episodes (p=ns), respectively, and respiratory symptoms were more frequent in the PT-A group: 42 (25%) cases vs. 24 (16%) in the C-A group (p=0.034). The presence of mucositis and shock was very low in both groups. Granulocyte colony-stimulating growth factors (G-CSF) were given in 70 (46%) episodes of the C-A arm and in 71 (43%) episodes of the PT-A arm (p=ns); the median treatment durations were 6 days in both groups. The duration of antibiotic treatment was also similar, with a median of 6.5 and 7 days, respectively (p=ns). Change in antibiotic treatment was recorded in 60 episodes (39%) in the C-A group and in 55 (33%) episodes in the PT-A group (p=ns), and amphotericin was used in 28 (18%) and 26 episodes (16%), respectively (p=ns).
Clinical classification of infectious episodes
Approximately one third of the febrile episodes had a microbiologically documented infection ( and gastrointestinal. A clinically documented infection was observed in 39 (26%) episodes in the C-A group and in 47 (28%) episodes in the PT-A group; the main diagnoses in this group were pneumonia and gastroenteritis. Finally, the episode was classified as fever of uncertain origin in 60 (39%) cases in the C-A arm compared to 77 (47%) cases in the PT-A arm (p=ns).
Microbiologically documented infections
Bacteremia was documented in 41 episodes in the C-A arm vs. 28 episodes in the PT-A arm (p=0.03) ( Table 3) . Grampositive bacteria (mainly coagulase-negative staphylococci) were isolated in 19 (12%) episodes in the C-A arm compared to 9 (5%) episodes in the PT-A arm (p=0.05).
Gram-negative bacteria were isolated in 22 (14%) and 19 (11%) episodes, respectively (p =ns); E. coli and P. aeruginosa were the predominant pathogens. Urine cultures were positive in 20 episodes in the C-A group and in 17 episodes in the PT-A group, with E. coli being the most frequently isolated pathogen. Cultures of the CVC line were positive for gram-positive bacteria in 3 and 2 episodes, respectively.
Toxicity
Toxicity attributable to the antibiotic regimen was observed in 6 (4%) cases in the C-A group (four rash, one renal, one hypoacusia) and in 5 (3%) cases in the PT-A group (two rash, three renal) (p=ns). In all four cases of renal toxicity, amikacin was discontinued and, except in one case, creatinine levels reached a maximum of 2.5 mg/dl and normalized at discharge.
Outcomes
The antibiotic success rate (no change or addition of antibiotics) was recorded in 89 (59%) of episodes in the C-A arm and in 105 (64%) episodes in the PT-A arm (p=ns) ( Table 3 Microbiological isolates both treatment arms were observed when the infection was microbiologically or clinically documented as compared to the episodes with fever of uncertain origin (see Table 5 ). When only bacteremic episodes were analyzed, we found no significant differences among the two treatment arms with respect to comorbidity, degree of neutropenia, treatment failure (need to change or add antibiotics), mortality related to infection, or 28-day mortality.
Resolution of the febrile episode (with or without change in therapy) was observed in 140 (92%) episodes in the C-A group and in 152 (92%) episodes in the PT-A group. Superinfection was diagnosed in 15 episodes: seven episodes in the C-A group (three coagulase-negative staphylococcus catheter-related infections, two urinary tract infections due to Enterococcus sp., and two cases with pneumonia) and eight episodes in the PT-A group (one coagulase-negative staphylococcus catheter-related infection, one Enterococcus sp. bacteremia, five cases of pneumonia, and one peritonitis). The 28-day mortality (all-cause) was also similar in both groups: 15 cases (9.9%) and 17 cases (10.5%) (p=ns), respectively; mortality related to infection was observed in six cases in both arms (3.9% vs. 3.6%), respectively. When the number of episodes per patient was taken into account, there was a statistically significant difference in all-cause A separate analysis of the first episode of febrile neutropenia in all 190 patients was performed (88 patients randomized to cefepime plus amikacin vs. 102 randomized to piperacillin/tazobactam plus amikacin). We did not find any statistically significant differences with respect to comorbidity, underlying disease, disease status, autologous peripheral blood stem cell transplantation, degree or duration of neutropenia, risk factors for infection, duration of fever, clinical classification of the episode, baseline positive blood cultures, antibiotic success without changing or adding antibiotics, resolution of the febrile episode, toxicity, or mortality. We only found a significant difference with respect to the duration of antibiotic treatment (cefepime arm 5.56 , in the piperacillin/tazobactam arm, p=0.02) ( Table 6 ).
Discussion
In our trial, the overall resolution of the febrile episode was observed in 92% of cases in both groups, similar to other studies [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
In Europe, the drug labeling of piperacillin/tazobactam recommends the use of 4 g/500 mg /6 h, and for cefepime the administration of 2 g/8 h. IDSA guidelines [26] do not specify the optimal dose to be used. Most published trials have evaluated the standard doses of piperacillin/tazobactam or cefepime [6, [17] [18] [19] [20] [27] [28] [29] [30] side, although some studies with lower doses [21, 31] have been conducted with good response rates. A synergistic effect against gram-negative bacteria and a lower incidence of bacterial resistance has been argued, favoring the classical combination therapy [26] . The addition of an aminoglycoside achieves a better response in the more profound neutropenic patients (<500 granulocytes/mm 3 ), as demonstrated in the study conducted by Tamura et al. [22] . A pharmacokinetic study in an in vitro model against two strains of P. aeruginosa showed that, in the mucoidproducing strain, the dose of cefepime 2 g/12 h was less effective than cefepime 2 g/8 h or cefepime 2 g/12 h plus tobramycin [32] ; these results could be explained by the synergy achieved with the addition of the aminoglycoside.
The population studied in our trial was similar to that of other studies with respect to the main disease (acute leukemia in approximately half of the cases) [4, 18, 20, 22, 27, 30] and the rates of granulocytopenia (>90% of episodes had <500 cells/mm 3 ). The time to defervescence was very short (a median of 3 days in both groups) and the need for changing or adding other antimicrobials was surprisingly low (39 and 33% of episodes, respectively) compared to other trials, with approximately two-thirds of the episodes (49-70%) in which the antibiotic therapy had to be modified [4, 18, 22] . The analysis of the episodes revealed a higher rate of clinically or microbiologically documented infection compared to other studies, and the analysis of efficacy showed a very high rate of response without any change in the antibiotic treatment (59 and 64% of episodes in the C-A and PT-A groups, respectively). These rates are higher than in a very similar study conducted by Sanz et al. [18] in 867 episodes comparing piperacillin/tazobactam (4 g/6 h) vs. cefepime (2 g/8 h) in combination with amikacin; in that trial, the rate of response without any change in the antibiotic was 49% in the C-A group and 51% in the PT-A group. Another recently published study [30] conducted in a very similar population also had lower response rates with monotherapy with cefepime (2 g/8 h) or piperacillin/tazobactam (4.5 g/6 h) (20.5 and 26.8% success rate, respectively). These results would indicate that the addition of an aminoglycoside to a low dose of piperacillin/tazobactam or cefepime favors better rates of response; even in patients with microbiologically documented infection (where the response rate is usually lower), our patients had a~50% chance of response without changing the therapy. As mentioned before, the emergence of resistance among gram-negative bacteria with new resistance determinants (ESBL, carbapenemases) that limit the use of some of the best drugs available has renewed the interest of the addition of an aminoglycoside to obtain a better response [16] .
Toxicity was low and the all-cause mortality rates was approximately 10% in both arms; these mortality rates are higher than those reported in other studies [4, 18, 21] . A possible explanation for this finding could be the higher median age of our patients and the number of patients that had had previous episodes of granulocytopenia.
An increased mortality rate in patients treated with cefepime compared with other β-lactam antibiotics has been reported [33] and a meta-analysis supports these results [34] . Our interim analysis with the first 186 episodes showed the same trend, with an all-cause mortality of 15% (13/86) in the cefepime arm vs. 5% (5/100) in the piperacillin/tazobactam group, relative risk (RR) 3.02 (95% CI, 1.12-8.14) [35] . However, this trend was no longer present at the end of the study (RR, 0.99). Interestingly enough, a recent review of the initial metaanalysis of Nguyen et al. [36] and a new meta-analysis carried out by the FDA [37] indicate that cefepime is safe and not associated to an increased mortality.
Our study has some limitations. When it was designed, fever was defined as 37.8°C on two occasions separated by at least 4 h, and the current guidelines had not been published [26] . In addition, empirical treatment with vancomycin when fever persisted beyond 48 h was the most accepted practice in this setting, although currently, we do not add vancomycin empirically for persistent fever in granulocytopenic patients. For risk group classification, we now follow the MASSC score [38] in the management of febrile neutropenic patients, but at the time the study was designed, this classification had not been established, and the standard of care was to admit all patients to the hospital for intravenous broad-spectrum antibiotic therapy. The study was not blinded and physicians knew the specific β-lactam used to treat the febrile episode. The excellent response rates in both arms reduced the importance of this as a source of bias; likewise, similar mortality rates in both groups supports the results obtained. Furthermore, our endpoints were not prone to bias in interpretation because they were prospectively defined (e.g., clinical cure) or highly objective (e.g., survival). Three aspects of the openlabel design could have influenced the study results, namely, randomization to treatment, patient demographics, and clinical endpoints. Randomization was performed according to the predefined study protocol, and a demographic analysis revealed comparable populations in both arms for all characteristics examined, including, most importantly, the intensity of neutropenia. Clinical resolution of a febrile episode is not a subtle finding; hence, bias due to investigator assessment is also unlikely. We conclude that the magnitude of any bias, from the sources considered, is unlikely to account for the results observed in this study.
In summary, our results with low doses of C-A and PT-A were equally effective in terms of efficacy, defervescence, toxicity, and outcome, and the use of combination therapy achieved very good rates of response and low rates of toxicity. This low dosage strategy would reduce the costs of the antibiotic treatment without hampering efficacy, and it should be considered as an attractive alternative option in an environment of progressive resistance among gramnegative bacteria, due to the increasing prevalence of ESBL-producing organisms and the increasing erosion of carbapenems by the dissemination of carbapenemases.
